Jiangsu Recbio Technology Co Ltd
02179
Company Profile
Business description
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Contact
No. 888 Yaocheng Avenue
Medical High-tech District
Jiangsu Province
Taizhou
CHNT: +86 52388820888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
507
Stocks News & Analysis
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,135.90 | 19.50 | -0.21% |
| CAC 40 | 7,857.38 | 23.49 | -0.30% |
| DAX 40 | 23,774.57 | 29.51 | 0.12% |
| Dow JONES (US) | 46,316.07 | 68.78 | 0.15% |
| FTSE 100 | 9,316.80 | 16.96 | 0.18% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,591.15 | 107.09 | 0.48% |
| Nikkei 225 | 44,932.63 | 111.12 | -0.25% |
| NZX 50 Index | 13,292.36 | 159.80 | 1.22% |
| S&P 500 | 6,661.21 | 17.51 | 0.26% |
| S&P/ASX 200 | 8,848.80 | 20.50 | -0.23% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |